Avigen (Nasdaq:
AVGN), Alameda, Calif., has obtained an exclusive worldwide license to Lawrence Berkeley Laboratory's interest in a patent covering a potential new therapy for the treatment of Parkinson's disease jointly owned with Avigen.
Tickers featured: AMGN, AMLN,
AVGN, DNA, IDBE, ISIS, LGND, LLY, MAXM, MEDI, NABI, VVUS.
Tickers featured: ABGX, AGIX, AMGN,
AVGN, AZN, BGEN, CATG, CEGE, CHIR, CRGN, DNA, GNVC, HGSI, IDPH, IMCL, INCY, MEDI, MLNM, ONXX, OSIP, RHHVF, TLRK, VICL.
Tickers featured: AMGN, AMLN, ASH,
AVGN, CALP, CRGN, DRG, HCX, HGSI, HPQ, IBM, IDBE, ISIS, JNJ/ALKS, KERX, LLY, MAXM, MEDI, MLNM, MOT, NABI, ODAC, PFE/PHA, SQNM, TELK, TRMS, VRTX, VVUS.